SynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCT finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
NorthSea Therapeutics B.V.: NorthSea Therapeutics Initiates Phase 2A Trial of Orziloben (NST-6179) in Intestinal Failure-Associated Liver Disease (IFALD) finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
NorthSea Therapeutics to Present ICONA Phase 2b Data as an Oral Late-breaker Session at the 2023 AASLD Liver Meeting finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
NorthSea Therapeutics B.V.: NorthSea Therapeutics Receives FDA Rare Pediatric Disease Designation for SEFA-6179 for the Treatment of Intestinal Failure-Associated Liver Disease finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
enGene, Inc. and Forbion European Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-Listed Biotechnology Company... | May 17, 2023
Form 424B3 NewAmsterdam Pharma Co streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
NorthSea Therapeutics now has three phase II clinical stage assets in development based on its SEFA platform Top line results of Phase 2b ICONA trial with lead programme icosabutate for NASH expected
Former Pfizer Internal Medicine CSO joins the Board as an independent board member NorthSea Therapeutics B.V. ('NST'), a biotech company developing novel and innovative strategies for the treatment
Series C financing led by NEA Provides advancement of INV-202 Phase 2 clinical trial in Diabetic Kidney Disease in Q4 Inversago Pharma Inc. ("Inversago"), a clinical stage biotech company with a unique